A detailed history of Ubs Group Ag transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 11 shares of NVCT stock, worth $56. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11
Previous 13 15.38%
Holding current value
$56
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.16 - $7.23 $12 - $14
-2 Reduced 15.38%
11 $0
Q2 2024

Aug 13, 2024

SELL
$5.98 - $8.25 $45,489 - $62,757
-7,607 Reduced 99.83%
13 $0
Q1 2024

May 13, 2024

SELL
$6.69 - $11.0 $2,943 - $4,840
-440 Reduced 5.46%
7,620 $62,000
Q4 2023

Feb 09, 2024

BUY
$7.85 - $11.78 $33,629 - $50,465
4,284 Added 113.45%
8,060 $67,000
Q3 2023

Nov 09, 2023

SELL
$12.89 - $16.29 $2,616 - $3,306
-203 Reduced 5.1%
3,776 $48,000
Q2 2023

Aug 11, 2023

BUY
$12.62 - $18.4 $50,214 - $73,213
3,979 New
3,979 $63,000
Q3 2022

Nov 10, 2022

BUY
$7.09 - $13.0 $1,120 - $2,054
158 Added 254.84%
220 $2,000
Q2 2022

Aug 10, 2022

SELL
$7.02 - $20.44 $554 - $1,614
-79 Reduced 56.03%
62 $1,000
Q1 2022

May 16, 2022

BUY
$3.25 - $9.1 $458 - $1,283
141 New
141 $1,000

Others Institutions Holding NVCT

About Nuvectis Pharma, Inc.


  • Ticker NVCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,642,500
  • Market Cap $74.7M
  • Description
  • Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...
More about NVCT
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.